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ABSTRACT
Mesenchymal stem/stromal cells (MSCs) are widely studied by both academia and industry for a
broad array of clinical indications. The collective body of data provides compelling evidence of the
clinical safety of MSC therapy. However, generally accepted proof of therapeutic efficacy has not
yet been reported. In an effort to generate a more effective therapeutic cell product, investigators
are focused on modifying MSC processing protocols to enhance the intrinsic biologic activity. Here,
we report a Good Manufacturing Practice-compliant two-step MSC manufacturing protocol to gen-
erate MSCs or interferon c (IFNc) primed MSCs which allows freshly expanded cells to be infused
in patients on a predetermined schedule. This protocol eliminates the need to infuse cryopre-
served, just thawed cells which may reduce the immune modulatory activity. Moreover, using
(IFNc) as a prototypic cytokine, we demonstrate the feasibility of priming the cells with any bio-
logic agent. We then characterized MSCs and IFNc primed MSCs prepared with our protocol, by
karyotype, in vitro potential for malignant transformation, biodistribution, effect on engraftment
of transplanted hematopoietic cells, and in vivo toxicity in immune deficient mice including a com-
plete post-mortem examination. We found no evidence of toxicity attributable to the MSC or IFNc
primed MSCs. Our data suggest that the clinical risk of infusing MSCs or IFNc primed MSCs pro-
duced by our two-step protocol is not greater than MSCs currently in practice. While actual proof
of safety requires Phase I clinical trials, our data support the use of either cell product in new clini-
cal studies. STEM CELLS TRANSLATIONAL MEDICINE 2017;00:000–000
SIGNIFICANCE STATEMENT
Mesenchymal stem/stromal cells (MSCs) are one of the most widely studied cells for the devel-
opment of cellular therapies. While these cells are unequivocally safe to use in humans, the
efficacy of MSCs to treat diseases has not been established. Hence, current efforts are focused
on developing the technology to enhance the efficacy of MSCs. Here, we report a novel strat-
egy to prepare MSCs that would mitigate the potential reduction of cell potency observed
when infusing freshly thawed, cryopreserved cells. Additionally, we show extensive preclinical
data to support the safety of interferon g primed MSCs, which are designed to enhance the
immune modulatory potency of MSCs.
INTRODUCTION
Mesenchymal stem/stromal cells (MSCs) are
spindle-shaped, morphologically nondescript,
adherent cells with the remarkable capacity to
stimulate the body’s endogenous reparative mech-
anisms and modulate the immune response. These
properties offer countless opportunities for devel-
opment of novel therapeutics. Indeed, over the
last 2 decades, MSCs have emerged as one of the
most commonly studied cell therapies worldwide
[1]. This enthusiasm is based largely on the ease of
isolation and ex vivo expansion as well as the
capacity to infuse cells across HLA barriers render-
ing implementation of MSC studies far less com-
plex than other cell therapies. Moreover, the
encouraging results of innumerable preclinical
studies have prompted applications in a vast array
of disorders encompassing the spectrum of regen-
erative medicine and immune modulation. Perhaps
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STANDARDS, PROTOCOLS, POLICIES, AND REGULATIONS
FOR CELL-BASED THERAPIES
most importantly, the extraordinary safety profile in clinical trials to
date has created a favorable risk-benefit analysis for most disorders
lowering the threshold to launch pilot trials. The net result is an
abundance of early phase studies suggesting favorable response;
however, phase III studies in several diseases have failed to demon-
strate a significant therapeutic benefit [2]. These seemingly conflict-
ing results underscore the importance of the method of isolation,
expansion, and storage of the MSCs, as well as selection of the tar-
geted disease, eligibility criteria, and endpoints for clinical trials.
Another arena of research that has gained momentum as a
consequence of early phase successes is the effort to augment the
intrinsic biologic activity of MSCs or engineer the cells to confer
novel biologic activity. The high efficiency of gene transfer has led
to applications using MSCs to delivery gene therapy. The apparent
plasticity of MSCs in vitro opens the door to developing tissue cul-
ture conditions to shape the final cell product for a specific
application.
The immune suppressive properties of MSCs have garnered
considerable attention. Much effort is directed toward enhancing
this activity by treating MSCs with modulating cytokines, for exam-
ple, interferon g (IFNg) [3] or interleukin(IL)-17 [4]. These agents
explicitly enhance the immune suppressive potential of MSCs in
vitro and possibly in vivo. However, such ex vivo manipulation may
also fundamentally alter the cells in ways we have not yet recog-
nized possibly posing new, ill-defined risks to study subjects.
Only through human trials will the full range of potential toxic-
ities be revealed. Nonetheless, in an effort to lessen the prospect
of an unpredicted toxicity in a human subject, we sought to com-
prehensively assess the safety of IFNg-primed MSCs prepared
according to current Good Manufacturing Practice (cGMP) proto-
cols with animal and in vitro preclinical analyses. We assessed
MSCs and IFNg-primed MSCs prepared from the same donor in
parallel allowing us to attribute any identified toxicities specifically
to the IFNg priming distinct from the general manufacturing
protocol.
MATERIALS AND METHODS
Isolation, Primary Ex Vivo Expansion, and
Cryopreservation
Bone marrow (20 ml) was collected by routine aspiration
according to a protocol approved by the Institutional Review
Board and was promptly mixed with heparin/plasmalyte to a final
concentration of 12 U/ml heparin. The marrow, which did not
pass through particle filters, was promptly transferred to the cell
therapy laboratory where mononuclear cells (MNC) were isolated
by density centrifugation over Ficoll at 750g for 20 minutes. After
washing, MNC were transferred to CellSTACK culture vessels
(Corning, New York, www.corning.com) at a target density of 1.6
E05 cells per cm2 (range, 0.5–2) in D5 culture media consisting of
low-glucose Dulbecco’s Modified Eagle’s medium (DMEM) supple-
mented with 5% human platelet lysate (PLTmax, Mill Creek, Roch-
ester, MN, www.millcreekls.com), 2 mM GlutaMax (Gibco/Thermo
Fisher Scientific, Waltham, MA, www.thermofisher.com), 2 U/ml
preservative-free Heparin (USP), 10 mM N-Acetylcysteine (USP),
and 40 lg/ml gentamycin (USP). The cultures were washed at 2–3
days to remove nonadherent cells and replated after 7–10 more
days to disperse the adherent cells evenly over the surface. When
the adherent cells had expanded to approximately 80% conflu-
ence (2–3 weeks in culture), these Passage 0 (P0) cells were either
cryopreserved in D4 culture media (D5 minus the gentamycin)
with 10% DMSO and 20% PLTmax or split into CellSTACK culture
vessels at a target density of 2,000–3,000 cells/cm2 (range, 1,000–
5,000) and continued in culture for 1–2 weeks. When the P1 cells
attained about 80% confluence, the cells were collected from cul-
ture and cryopreserved. Depending on the size of the marrow har-
vest, the yield of MSCs and the number required, either P0 or P1
cells may be cryopreserved at 0.9–1.1 E06 cells/ml and stored in
liquid nitrogen vapor phase storage to support a single trial. A
sample of the cryopreserved population of MSCs underwent
release testing according to criteria developed in accordance with
recommendations of the Food and Drug Administration (http://
www.fda.gov/cber/guidelines.htm, Table 1) to validate our preclin-
ical cell stock.
Secondary Ex Vivo Expansion and Interferon c Priming
To allow the cells to recover from the detrimental effects of cryo-
preservation [5], MSCs were thawed in a 378C water bath, diluted
10-fold with prewarmed 378C D4 culture media and washed once
before being placed into tissue culture in D4 culture media at a
target density of 2,000–3,000 cells per cm2 (range, 1,000–5,000).
This culture will always be planned for a 7- or 9-day culture prior
to a patient’s scheduled infusion. Two days before the expansion
was complete, cells were fed with fresh D4 culture media contain-
ing 500 U/ml GMP-grade recombinant human IFNg (R&D
Table 1. Release criteria for primary and secondary expansions
Release test and methods Primary expansion sample Secondary expansion sample Release criteria
Microbial culture—Bactec automated
culture system, aerobic, and anaerobic
Fresh MSCs after addition
of DMSO, Precryopreservation
Spent culture media
2 days prior to harvest
No growth
Mycoplasma—MycoAlert
luminescent assay
Spent culture media
day of harvest
Spent culture media
day of harvest
Negative (borderline
result retested by PCR)
Endotoxin—Endosafe LAL
kinetic chomogenic
Test-thawed MSCs Final MSC product 5 EU/ml, primary;
5 EU/kg recipient
weight, secondary
Trypan Blue Viability Pre-cryopreservation MSCs NA Information only
Trypan Blue Viability NA Final MSC product 90%
%CD451—flow cytometry Fresh MSCs
Precryopreservation
Final MSC product 20%
%CD1051—flow cytometry Fresh MSCs
Precryopreservation
Final MSC product 70%
Gram Stain NA Final MSC product No organisms identified
Abbreviations: MSCs, mesenchymal stem/stromal cells; NA, not applicable.
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Systems, Minneapolis, MN, www.rndsystems.com). A sample of
spent media from each culture vessel was collected 2 days prior
to completion and tested for microbial contamination to satisfy
the appropriate release criteria. On the day of the planned infu-
sion, the cells were collected by trypsinization (Gibco), washed to
remove IFNg and then resuspended in infusion media (Plasma-
Lyte A [USP], 0.22% NaCl [USP], 2.5% Dextrose [USP], 0.5% human
serum albumin [USP]. This final cell product or spent media was
tested and met all release criteria which will be required in clinical
trials before transport to the subject’s bedside.
Cell Culture for In Vitro Malignant Transformation
GMP-prepared MSCs were seeded in culture with DMEM-LG
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Lawrenceville, GA) and 1% Penicillin-
Streptomycin (Mediatech) at a density of 3,000 cells/cm2. The cells
were monitored twice per week and the media was changed
weekly.When the MSC cultures were estimated to be 80% conflu-
ent, the cells were collected by trypsin-EDTA (0.25%) (Mediatech),
washed, and reseeded at 3,000 cells per cm2. The MSCs were seri-
ally passaged until senesce. All other studies, in vitro or in vivo,
used cells prepared in human platelet lysate.
Trilineage Differentiation Assay
GMP-prepared MSCs and IFNg primed MSCs were differentiated
to osteoblasts, adipocytes, and chondrocytes as determined by
staining with Alizarin Red S, Oil Red O, and Alcian Blue, respec-
tively, as previously described [6].
Animals
C57BL/6J and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were
purchased form Jackson Laboratories (Bar Harbor, ME) and trans-
genic C57BL6 mice with pancellular expression of the green fluo-
rescent protein (GFP) under control of the H2K promoter were
obtained from our laboratory colony [7]. Mice were maintained
under specific pathogen free condition in our AAALAC-accredited
animal research facility. All animal studies were approved by our
Institutional Animal Care and Use Committee at The Research
Institute at Nationwide Children’s Hospital.
Transplantation
Total body irradiation of wild type C57BL/6J mice (500 cGy3 2, 3
hours apart) was performed with an x-ray source (X-RAD 320: Pre-
cision x-ray Inc, North Branford, CT). After 48 hours, mice were
transplanted with 2 3 106 unfractionated GFP-expressing C57BL/
6 marrow cells and 250,000 human [8] or murine [9] MSCs via a
tail vein injection. Hematopoietic reconstitution was monitored
by serial complete blood counts (Hemavet 950FS, Drew Scientific,
Miami Lakes, FL) and flow cytometric analysis for GFP expression
(donor cells).
Quantitative PCR
Human MSCs were detected in mouse tissues using the quantita-
tive polymerase chain reaction (qPCR) technique originally
described by Francois et al. 2006 [10]. Genomic DNA was
extracted from mouse tissue using the QIAamp DNA mini kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s instruc-
tions. The amount of human DNA in each sample was quantified
by amplification of the human beta-globin gene (HBB), while
amplification of the endogenous mouse Receptor-Associated Pro-
tein at the Synapse gene (RAPSYN) served as an internal control.
One hundred nanograms of DNA extracted from bone, brain, skin,
stomach, heart, muscle, bone marrow, lung, liver, kidney, and
spleen was amplified using Taqman Fast Advanced Master Mix
and a Step-One Plus Real Time PCR system (Applied Biosytems,
Foster City, CA, www.thermofisher.com) according to the manu-
facturer’s instructions. The following primers and probes were
used: HBB-forward 50-GTGCACCTGACTCCTGAGGAGA-30, HBB-
reverse 50-CCTTGATACCAACCTGCCCAGG-30, HBB-probe 50-FAM-
AAGGTGAACGTGGATGAAGTTGGTGG-TAMRA-30, RAPSYN-forward
50-ACCCACCCATCCTGCAAAT-30, RAPSYN-reverse 50-ACCTGTCCGTG
CTGCAGAA-30, RAPSYN-probe 50-FAM-CGGTGCCAGTGATGAGGTTG
GTC-TAM RA-30.
Karyotype Analysis
Cells were harvested from confluent flasks, using Hanks Balanced
Salt Solution (Gibco/Life Technologies, Thermo Fisher Scientific)
and Trypsin-EDTA 1X (Gibco), and transferred to petri dishes with
cover slips. Once the cells had reached 50%–60% confluency, the
cover slips were harvested using standard methods (ACT Cytoge-
netics Laboratory Manual, 2nd edition, Barch, MJ, ed. Raven Press,
1991); briefly, exposure to colcemid for 30 mintes (Gibco), fol-
lowed by warm hypotonic solution (0.7% sodium citrate) for 20
minutes, then by a 2-minute pre-fixation in 3:1 Carnoy’s fixative
(3:1 methanol: glacial acetic acid) and then three additional, 10-
minute washes with the same fixative. The metaphase spreads
were then GTG-banded using standard methods [11]. The cultured
cells were analyzed following the College of American Pathologist
clinical guidelines for non-neoplastic disorders; namely, 20 meta-
phase cells were counted and a minimum of five cells were ana-
lyzed band for band and karyotyped.
Soft Agar Colony Forming Assay
Anchorage-independent colony formation was assayed in six-well
tissue culture plates containing 0.4% agarose medium over a 0.8%
agar base layer. MSCs, both with and without IFNg–priming, as
well as the ES-2 carcinoma cell line, were seeded at 20,000 cells
per well and incubated at 378C. Twice weekly, 0.5 ml complete
media was added to each well. After 14 days, colonies were
stained with 0.01% Crystal Violet for 1 hour.
Gene Expression
Following assessment of the quality of total RNA using Agilent
2100 bioanalyzer and RNA Nano Chip kit (Agilent Technologies,
Santa Clara, CA, www.agilent.com), RNA was DNAse treated and
2.5 mg was subjected to rRNA with Ribo-ZeroTM rRNA removal kit
for human/mouse/rat (Illumina). To generate directional signal in
RNA seq data, libraries were constructed from first strand cDNA
using ScriptSeqTM v2 RNA-Seq library preparation kit (Epicentre
Biotechnologies, WI, www.epibio.com). Briefly, 50 ng of rRNA-
depleted RNA was fragmented and reverse transcribed using ran-
dom primers containing a 50 tagging sequence, followed by 30 end
tagging with a terminal-tagging oligo to yield di-tagged, single-
stranded cDNA. Following purification by a magnetic-bead based
approach, the di-tagged cDNA was amplified by limit-cycle PCR
using primer pairs that anneal to tagging sequences and add adap-
tor sequences required for sequencing cluster generation. Ampli-
fied RNA-seq libraries were purified using AMPure XP System
(Beckman Coulter, Brea, CA, www.beckman.com). Quality of libra-
ries were determined via Agilent 2200 Tapestation using High Sen-
sitivity D1000 screen tape, and quantified by Qubit flourometer
with dsDNA BR assay (Invitrogen by Thermo Fisher Scientific).
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Paired-end 150 bp sequence reads were generated using the Illu-
mina HiSeq 4000 platform.
Bioinformatic Analysis
A median of 65 million paired-end 150 bp RNA-Seq reads were
generated for each sample (range, 57 to 72 million). Each sample
was aligned to the GRCh38.p6 assembly of the Homo Sapiens ref-
erence from NCBI (http://www.ncbi.nlm.nih.gov/ assembly/
GCF_000001405.31/) using version 2.5.0c of the RNA-Seq aligner
STAR (http://bioinformatics.oxfordjournals.org/content/early/
2012/10/25/bioinformatics.bts635). Transcript features were iden-
tified from the GFF file provided with the GRCh38.p5 assembly
from NCBI and raw coverage counts were calculated using HTSeq
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.html).
The raw RNA-Seq gene expression data was normalized and post-
alignment statistical analyses performed using DESeq2 [12] (http://
genomebiology.com/2014/15/12/550) and custom analysis scripts
written in R. Comparisons of gene expression and associated statis-
tical analysis were made between different conditions of interest
using the normalized read counts. All fold change values are
expressed as test condition/control condition, where values less
than one are denoted as the negative of its inverse (note that there
will be no fold change values between21 and 1, and that the fold
changes of “1” and “21” represent the same value). Transcripts
were considered significantly differentially expressed using a 10%
false discovery rate (DESeq2 adjusted p value .1) and a fold-
change cut-off of 2 between the control and test samples.
Flow Cytometry
Flow cytometry analysis was performed on an LSR II (BD Bioscien-
ces, San Jose, CA, www.bdbiosciences.com) cytometer using the
following antibodies: anti-mouse CD45-APC, Sca1-PerCP/Cy5.5,
CD150-PE (eBioscience/Thermo Fisher Scientific), Ter119-APC, lin-
eage cocktail-Pacific Blue, c-Kit-APC; anti-human HLA-DR-PE, HLA-
ABC-APC, PD-L1-PE, PD-L2-APC, B7-H2-PE, B7-H3-APC, CD80-PE/
Cy5, CD86-PE/Cy7, CD40-AlexaFluor647 (Biolegend, San Diego,
CA, www.biolegend.com). Data were analyzed using FlowJo ver-
sion 7.6.5 (Tree Star, Inc., Ashland, OR, www.scientificcomputing.
com).
Clinical and Anatomic Pathology
Mice were euthanatized by carbon dioxide asphyxiation. Whole
blood was collected by percutaneous cardiac puncture following
euthanasia. Complete blood counts with 6-part white blood cell
differential were performed on a portion of EDTA anti-coagulated
whole blood (FORCYTE Autosampler 10, Oxford Science, Inc.,
Oxford, CT). Following coagulation of the remaining whole blood
at room temperature for 30 minutes, the clotted blood was centri-
fuged at 3,000 rpm for 5–10 minutes at 4oC. Biochemical profiles
were performed on serum samples (VetACE, Alfa Wasserman,
West Caldwell, NJ). Complete postmortem evaluations were per-
formed, and body and organ (thymus, heart, lungs, liver, spleen,
kidneys, adrenals, testes and epididymides, ovaries and uterus,
brain) weights were obtained on all mice. All tissues were fixed in
10% neutral buffered formalin with the exception of the skull,
sternum, vertebral column and rear legs which were fixed in
Decalcifier I (Leica Biosystems, Wetzlar, Germany, www.leicabio
systems.com) for 48 hours. All tissues were processed by routine
methods and embedded in paraffin wax. Sections (4 lm) were
stained with hematoxylin and eosin (HE), and evaluated with an
Olympus BX45 light microscope with attached DP25 digital camera
(B & B Microscopes Limited, Pittsburgh, PA, www.bbmicro.com,
and Nikon Instruments, Elgin, IL, www.nikoninstruments.com) by
a veterinary pathologist (KMDL) certified by the American College
of Veterinary Pathologists (ACVP).
Statistical Analysis
Data were analyzed for statistical significance with a Student t test
for two group comparisons and one-way ANOVA (with Tukey’s
posttest analysis when appropriate) for multiple comparisons.
Analyses were performed with Prism, version 6.03 (GraphPad
Software, Inc., San Diego, Ca, www.graphpad.com). p< .05 was
taken to be statistically significant.
RESULTS
MSC Manufacturing Process Validation
We developed a 2-step manufacturing process to prepare the clin-
ical cell product (Fig. 1). To validate the manufacturing protocols
and assess pharmacology/toxicology of the clinical product, we
prepared MSCs from a single donor with and without IFNg–pri-
ming of the cells. MSCs isolated from a donor and expanded ex
vivo in parallel tissue culture flasks exhibit indistinguishable gene
expression profiles [13] indicating any observed differences
between the cell populations in this study must be due to the
effect of IFNg. For MSC manufacturing intended for clinical trials,
the bone marrow donor must satisfy the hematopoietic cell donor
criteria described in the current standards of Federation for
Accreditation of Cellular Therapy (FACT).
Second Expansion and IFNc Priming
Recovery of viable MSCs from cryopreserved stocks was 97%6
9% (mean6 standard deviation, n5 6). Over the 7-day expansion,
the MSCs underwent 3.16 0.9 (n5 5) population doublings with
a doubling time of 2.56 0.8 days (n5 5). The final yield of cells
was 23,3006 11,000 MSCs per cm2 (n5 5) and the viability was
uniformly 93%. There was no significant difference in any of
these expansion parameters or viability following IFNg exposure
for the last 2 days of culture. At the completion of the 7-day
expansion, with/without INFg exposure, the cells were collected
from the culture vessels by trypsinization, washed twice in phos-
phate buffered saline to remove residual IFNg and resuspended in
infusion media. ELISA measurement of IFNg (linear range 15–
1,000 pg/ml, Table 2) of samples taken at multiple steps during
trypsinization and wash showed that the PBS rinse of the culture
vessel after removal of the IFNg-containing media contained 86
pg/ml (approximately 300-fold reduction), while both cell washes
as well as the gMSCs in infusion media contained undetectable
levels (calculated level of <1 pg/ml which is below the level of
assay sensitivity).
MSC Stability
At the conclusion of the expansion, MSCs and gMSCs were each
collected by trypsinization, washed, and suspended in infusion
media at a concentration of 43 106 cells per ml. The cell suspen-
sions (MSCs, n5 2; gMSCs, n5 2) were each individually drawn
up into a syringe and maintained on a vertical rotator at room
temperature. Due to the indistinguishable results, we analyzed
the 4 groups together. After 4 hours, 93.3%6 10.2% of cells were
recovered and the viability was equivalent from the initial suspen-
sion (95.5%6 5.1% vs. 98.2%6 2.1%, respectively, p5 .22,
n5 4). These data indicate that the cells remain stable for 4
hours after collection from the expansion culture and suspension
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in infusion media which is sufficient time to complete release test-
ing and transport to the subjects’ bedside.
Next, MSCs (n5 2) and gMSCs (n5 2) were slowly passed
through a syringe and tubing to simulate a clinical slow intrave-
nous “push” infusion.We found 94.6%6 3.2% of cells were recov-
ered without loss of viability (97.7%6 1.5% vs. 98.2%6 1.1%,
p5 .56, n5 4) in the effluent supporting the assertion that a sub-
ject will receive the intended dose of viable cells.
Product-to-Product Variability
MSCs obtained from three different healthy donors were isolated
and IFNg-primed according to our GMP-protocol (Fig. 1). RNA iso-
lated from the MSCs and the corresponding gMSCs from the
same donor was assessed by RNA Seq. Principal component analy-
sis (PCA) using the normalized expression values for the 500 genes
with the highest variance, shows distinct clustering of the three
gMSC samples from MSCs, with the first principal component
accounting for 86% of the variance (Fig. 2A). This analysis also
showed a separation of the three patients’ samples, but this only
accounted for 8% of the variance. While the preponderance of
variation was due to IFNg priming, the cytokine produces a similar
variance in each of the patients; thus, IFNg priming does not
introduce additional interpatient variation than what intrinsically
exists in MSCs. Like PCA, Euclidean distance was calculated to
assess the overall similarity between samples (Fig. 2B). This analy-
sis revealed tight hierarchical clustering of the three treated or
untreated samples and distinct separation was clearly visible
between the two groups. To illustrate the relative gene expression
profile of the gMSC versus MSCs, the 20 most differentially
expressed genes are represented graphically as a heat map (Fig.
Figure 1. Schematic representation of the 2-step GMP manufacturing process. (A): The isolation and primary expansion of MSCs through
cryopreservation (B) the thawing and secondary expansion of MSCs. the opportunity for cytokine priming, if appropriate, is shown. See text
for details. Abbreviations: MNC, mononuclear cells; MSCs, mesenchymal stem/stromal cells.
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2C). Supporting Information contains a complete list of differen-
tially expressed genes when comparing IFNg-primed MSCs with
conventional MSCs (Supporting Information Fig. 1). Overall, the
most highly upregulated pathway is associated with antigen pre-
sentation. Of the immune modulating cytokines, IL6, IL15, and
IL32 were upregulated while IL16 and IL11 were downregulated;
however, only IL6 was expressed at a substantial level. We did not
identify upregulation or downregulation of proto-oncogenes or
tumor suppressor genes, respectively.
Karyotype
The final MSC product that would be infused in a patient was
assessed for the integrity of the chromosomes (Supporting Infor-
mation Fig. 2). Twenty cells in metaphase from the standard MSC
preparation and IFNg-primed MSCs were examined. All exhibited
modal number of 46 chromosomes including two X chromo-
somes. No consistent structural or numerical abnormalities were
detected. All five cells assessed for G-banding from each prepara-
tion displayed a normal pattern.
cMSC Phenotype
IFNg-primed MSCs express HLA Class I and II molecules, as well as
PD-L1 and PD-L2, but not CD80 or CD86 as expected (Fig. 3).
gMSCs did not express B7-H2, but highly expressed B7-H3, an
immune regulating molecule that may provide positive or nega-
tive costimulatory signals [14]. Finally, gMSCs expressed low level
CD40.
MSCs and gMSCs underwent in vitro differentiation to osteo-
blasts, adipocytes, and chondroblasts. Both cell preparations dif-
ferentiated similarly as determined by Alizarin Red S, Oil Red O,
and Alcian Blue histochemical staining, respectively.
In Vitro Malignant Transformation
To further asses the propensity of the clinical product to undergo
malignant transformation during cell manufacturing, samples of
MSCs and gMSCs, obtained at the completion of cGMP-
production that would be infused into a human subject, were
placed in routine tissue culture (DMEM-LG, 10% FBS) and serially
passaged until senescence. Initially, the doubling time was 2–3
days and then slowed to 19–21 days by 3 months. At 2 months
(10 passages), the cells were observed to spread on the plastic tis-
sue culture surface assuming widened morphology, in contrast to
the spindle shape of younger, actively replicated cells (Supporting
Information Fig. 3). Subsequently, the cells progressively sponta-
neously released from the plastic surface. Throughout the 6-
month interval of in vitro observation, MSCs and gMSCs similarly
expanded showing no effect of IFNg exposure during the cell man-
ufacturing. Moreover, both cells populations expanded evenly
without emergence of a rapidly replicating subpopulation.
Next, clinical GMP-manufactured products were assessed by
soft agar colony forming assay to detect anchorage-independent
clonal proliferation (Fig. 4). The positive control (ES-2 carcinoma)
demonstrates robust colony formation with several large colonies
and too numerous to count small colonies. Agar plates with MSCs
or gMSCs were devoid of any colony formation similar to the neg-
ative control.
Biodistribution
To determine the biodistribution of the clinical product in healthy
NSG mice, we infused 250,000 MSCs (n5 6) or gMSCs (n5 6), or
200 ll saline (n5 6, controls). At graded intervals, we assessed
DNA isolated from freshly harvested tissues for the evidence of
MSCs (human DNA) with a quantitative PCR assay using primers
specific for a single copy human (HBB) or mouse (RABSYN) gene
(Supporting Information Table 2). The assay was considered nega-
tive if a threshold (Ct) was not attained by 36 cycles of amplifica-
tion (limit of linear response). Analysis of standards, comprised of
mixing DNA derived from human MSCs with murine DNA demon-
strated a quantitative sensitivity of 0.05% human tissue (MSCs)
within murine tissue samples and complete specificity (no false
positives, n5 5) within the experimental limits. We intermittently
detected 0.01% human tissue, but the Ct (>36) deviated from lin-
earity. Assay of tissues obtained from NSG mice without MSC infu-
sions (negative controls) confirmed the specificity. At 24 hours
after infusion, we unambiguously identified lung-derived DNA as
human representing MSCs that had, as expected, presumably
lodged in the pulmonary capillary beds. Human DNA (MSCs) was
undetectable in all other tissues. By day 7, all tissues were devoid
of detectable human cells.
Engraftment and Hematopoietic Reconstitution After
Marrow Cell/MSC Cotransplantation
Five cohorts of C57BL/6J mice were transplanted 48 hours after
total body irradiation (500 cGy3 2 doses, 3 hours apart) with 13
106 GFP1 marrow cells and 250,000 ex vivo expanded murine
MSCs, murine gMSCs, GMP human MSCs, or GMP human gMSCs.
The final cohort did not receive MSCs (negative control). All
cohorts recovered leukocytes by day 17 (Fig. 5A) with >98%
donor-derived hematopoiesis indicating that neither the murine
nor human cells impaired engraftment or the kinetics of hemato-
poietic reconstitution (Fig. 5B). Unexpectedly on day 21, the four
cohorts of mice co-transplanted with one of the MSC prepara-
tions, had significantly more leukocytes than the mice trans-
planted only with hematopoietic cells (Fig. 5A). The increased
count was specifically due to increased lymphocytes (Fig. 5C) but
the CD4:CD8 ratio did not vary among the five cohorts (3–5:1)
and CD41CD251 cells were consistently<1% of all T cells.
In Vivo Toxicity of MSCs
NSG mice were intravenously (tail vein) infused with 250,000
MSCs (n5 6), gMSCs (n5 6), or saline (n5 6) without any
Table 2. Residual Interferon g in cell washings and Infusion
mediuma
Test Media
Expanded
MSCs
Expanded MSCs with
(48 hours) IFNg priming
Fresh media6 IFNg,
500 U/ml (control)
NAb 23,489c
Final culture medium 7 22,481c
PBS plate rinse NDd 86
Wash #1 ND ND
Wash #2 ND ND
Infusion medium (0 hours) ND ND
Infusion medium (6 hours) ND ND
aInterferon g was measured by ELISA and reported as pg/ml.
bNA, not applicable. Interferon g was not added to this fresh medium.
cDetermined by diluting media 1:50; measured value was in the linear
range.
dND, not detected.
Abbreviations: IFNg, interferon g; MSCs, mesenchymal stem/stromal
cells.
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preparative regimen. This dose approximates 1 3 107 MSCs/kg.
There were no peri-infusion adverse events. All mice thrived with-
out evidence of toxicity. The heightened human IL6 secreted from
the gMSCs, which can react with murine tissues, did not cause
any discernable toxicity. At 10 weeks after infusion, 3 mice from
each group were euthanized and underwent a comprehensive
post mortem examination. The remaining 3 mice in each group
were followed for long-term evaluation. One mouse which was
infused with MSCs died of undetermined causes at 21 weeks. The
3 control mice, 2 remaining MSC-infused mice, and all 3 gMSC-
infused mice are alive and well 16 months after infusion suggest-
ing that the infused cells have not given rise to a malignancy up to
this time point.
Post-Mortem Examination MSC- and cMSC-Infused NSG
Mice
In an effort to identify occult organ toxicity or tumor formation,
three mice from each group (controls, MSC- and gMSC-infused)
were assessed by post-mortem examination. At the time of eutha-
nasia (10 weeks after cell infusion), all mice were active, healthy-
appearing, and feeding well. The complete blood counts and white
blood cell subset proportions were within the expected range for
NSG mice and the three groups were not statistically different.
Similarly, serum chemistries were within the normal range for all
mice. The mean body weight did not differ among the groups.
We did not find any abnormalities by gross examination of the
internal organs. Moreover, there were no abnormal tissue masses
that could represent a tumor indicating the absence of occult
malignancy at 10 weeks post-infusion. The mean weight as a per-
centage of body weight for each organ was comparable among
the groups.
By microscopic examination of paraffin embedded tissue sec-
tions, we did not find any pathologic lesions or any histologic
lesions attributable to either cell treatment. Furthermore, we did
not find evidence of evolving malignancies in situ. Importantly,
examination of the lungs revealed an unequivocal absence of his-
topathology in all mice (cell infused mice and controls) demon-
strating the lack of occult pathology which would be potentially
attributable to the MSCs (Fig. 6A). Histologic examination of the
spleen revealed the expected lymphoid hypoplasia consistent
with the NSG phenotype and extramedullary hematopoiesis
which is physiologic in mice. In two MSC-infused mice, but none
among the controls or gMSC-infused animals, we identified sple-
nic foci of osseous metaplasia (Fig. 6B), which is not uncommon in
murine tissues, including NSG mouse spleens [15–18].
DISCUSSION
The principal conclusion from our preclinical data is that the risk
of cell therapy using gMSCs is no greater than MSCs, which have
Figure 2. Clustering of global transcriptional responses of MSCs following priming with IFNg. (A): Principal Component Analysis (PCA) of dif-
ferential gene expression of MSCs (open shapes) and gMSC (filled shapes) from each donor (same color). (B): Euclidean distance between
samples to assess overall similarity among the samples. The darker blue indicates a shorter distance, more similar; lighter blue indicates
greater distance, less similar. (C): Heat map analysis of RNA-Seq gene expression data from MSCs and gMSC. The heatmap was generated
using the normalized expression values for the 20 most upregulated and downregulated genes following interferon g priming. Color code
indicates relative expression; red highest, blue lowest. Abbreviation: MSCs, mesenchymal stem/stromal cells.
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an outstanding, well-established safety prolife. Moreover, MSCs
prepared according to our two-step protocol and infused intrave-
nously do not show new, previously unrecognized risks to cell
therapy. Lacking identified toxicity, or even implications of adverse
outcomes, our data provide compelling support to proceed with
clinical investigation to assess gMSCs in human subjects for appro-
priate target disorders.
We have described a two-step cGMP-compliant manufactur-
ing protocol to generate IFNg-primed MSCs for clinical trials. Our
protocol overcomes two current major barriers in the production
of MSC-based cellular therapeutics: (a) cells must be available on
demand and (b) cryopreserved, freshly thawed cells may have
reduced potency as the infusion product. In actuality, these two
challenges are closely related. The most common approach to pro-
viding cells on demand is to cryopreserve manufactured cells
which can be thawed and infused at the designated time. How-
ever, previously cryopreserved, freshly thawed MSCs may lack the
requisite immune suppressive activity to be of therapeutic value
[5, 13]. Thus, we isolate, partially expand, and cryopreserve MSCs
specified for a given protocol. MSC isolation by methods [19, 20]
other than Ficoll and adherence will not detract from the value of
the two-step protocol. Moreover, cells remaining cryopreserved
for the duration of typical early phase clinical trial will not affect
the secondary expansion potential or potency of the freshly
expanded product [21]. Upon scheduling a patient for MSC ther-
apy, we can thaw and further expand for 7 days, which is sufficient
to abrogate the detrimental effects of cryopreservation [5]. Then,
we can culture in the presence of IFNg if appropriate and collect
freshly expanded, IFNg primed MSCs for infusion. Thus, we can
reliably infuse a patient/subject at a previously scheduled time,
that is, on demand, with freshly expanded MSCs.
Ideally, a cryoprotectant would be identified allowing cryopre-
served, freshly thawed MSCs to maintain the immune modulatory
activity for therapeutic applications. In lieu of such an agent, our
manufacturing protocol will subvert these obstacles allowing for
unimpeded patient-based MSC research.
The most worrisome complication of any cell therapy is the
risk of malignant transformation of the therapeutic cell product
after infusion into a patient. We have presented six lines of evi-
dence to address this issue. First, RNA Seq analysis did not show
upregulation of a proto-oncogene or downregulation of a tumor
suppressor gene. Second, karyotype analysis did not show evi-
dence of any abnormality, random or clonal. Third, prolonged in
vitro culture did not reveal outgrowth of a predominate clone.
Figure 3. Immunophenotype of interferon g primed Mesenchymal stem/stromal cell (MSCs). Flow cytometric analysis of select surface
marker expression on gMSCs (solid line) and the isotype control (shaded peak).
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Fourth, soft agar colony forming assay definitely showed the
absence of anchorage-independent clonal proliferation. Fifth, at
10 weeks after infusion into NSG mice, post-mortem examination
did not find evidence of occult tumors. Finally and most impor-
tantly, we have not identified clinical evidence of tumor formation
in NSG mice 16 months after infusion. Collectively, these data
comprise a compelling package to suggest that the risk of malig-
nant transformation of gMSC is not different than that of MSCs,
for which this catastrophic complication has never been reported.
Our biodistribution data suggest that both MSCs and gMSC
lodge in the pulmonary capillary beds with the first 24 hours after
intravenous infusion and then either are cleared by pulmonary
macrophages or pass through the capillaries. We did not find evi-
dence of specific or random tissue localization subsequent to 24
hours at the limit of our assay sensitivity; however, our findings
differ from the tissue distribution of intravenously infused MSCs
often reported [22]. Seeking to emulate a clinical study, we
infused 250,000 MSCs/animal which is approximately 10 3 106
MSCs/kg (25 g/mouse), a large but clinically relevant dose.
Moreover, the quantitative sensitivity of our assay was 0.05% and
the absolute sensitivity was 0.01%, similar to others [10] and a
clinically relevant level of detection. By contrast, studies focused
on the biology of MSCs have infused 5 3 106 MSCs/animal which
is approximately 200 3 106 MSCs/kg or used an assay with far
greater sensitivity [22, 23]. We suggest our findings indicate any
MSCs that may reside throughout the body after our clinical-like
infusion exist below the clinically relevant detection, except for
the risk of malignant transformation which we have shown is no
greater than for MSCs in current clinical trials. Thus, the biodistri-
bution of gMSC is not predicted to confer any additional risk com-
pared to MSCs.
The manufacturing protocol we describe includes the prepara-
tion of a supply of MSCs cryopreserved at very low passage
(typically P0 or P1) earmarked for a restricted number of subjects
enrolled in a specific clinical trial. This approach allows for all cells
to be used in an early phase clinical trial to be obtained from a sin-
gle or very few donors and limits the extent of ex vivo expansion.
Establishing a master cell bank will likely be required for Phase II
and certainly Phase III trials. However, preparing a dedicated sup-
ply of cells for a single protocol without preparing a master cell
bank, as we describe, is feasible for smaller Phase I trials and
should facilitate implementation of formal protocols. The key
advance for the MSC field is that such manufacturing should elimi-
nate the need for anecdotal reports of MSC therapy as prospec-
tive hypothesis-driven early phase clinical trials are needed to
identify the most promising directions for cell therapy research.
Of note, samples of cells from the product intended for infusion
should be archived for a complete biologic characterization (e.g.,
transcriptomics, proteomics, and/or metabolomics) in anticipation
of a successful Phase I trial creating the need to more rigorously
understand the biology of the specific therapeutic cells and repro-
ducibly manufacture the cell product.
A fundamental concern when processing cells using a cytokine
treatment is whether residual cytokine will be infused into the
human subject. For IFNg, this concern is heightened because of
the potential impact on hematopoiesis [24], such as triggering
aplastic anemia [25]. A normal range for serum IFNg is not avail-
able; however, a recent study reported healthy control subjects
with a median serum concentration of 11.40 pg/ml (95% confi-
dence interval of 7.80–31.75, n5 44, >21 years, M:F, 1:1) [26]. A
second study reported serum level of 236 13 pg/ml (mean6
standard deviation, n5 11 ages 13–40) [27]. In our study, we
found undetectable levels of IFNg after the first cell washing
(Table II). Even if we assume 10 pg/ml residual IFNg in the infusion
media (an enormous overestimation), a dose of 2 3 106 MSC/kg
(infusion medium cell concentration of 43 106 MSCs/ml, assume
distribution in the blood only) would raise the subject’s serum
IFNg level less than 0.2 pg/ml, a clinically inconsequential
variation.
Two findings on the post-mortem exam merit consideration.
First, the lungs in all mice lacked clinically-silent histopathologic
lesions. Since MSCs transiently lodge in the lungs after intrave-
nous infusion [28, 29], investigators are often especially concerned
about pulmonary complications. Our data show that infusion of
human MSCs and gMSCs into mice do not seem to induce occult
changes in the lungs up to 10 weeks after infusion. Thus, the risk
of long-term complications would seem to be exceedingly low.
The second interesting finding is the foci of osseous metapla-
sia in the spleen of two MSC-infused mice but none of the con-
trols or gMSC-infused animals. This murine observation is
especially notable given that ectopic ossification is a long-standing
concern with MSC therapy. The National Toxicology Program
(Department of Health and Human Services) advises preclinical
toxicology investigators to remain cognizant of pathology intrinsic
to the animal model to avoid incorrectly attributing an observed
event to the investigational agent [30]. Osseous metaplasia is not
uncommon in murine tissues, especially in lung and kidney of vari-
ous strains of mice, but has also been reported in the spleen of
NSG mice [15–18]. Moreover, our veterinary pathology service
has frequently observed splenic osseous in mice of multiple
strains (unpublished observation, Krista LaPerle, D.V.M., Ph.D.).
Importantly, osseous metaplasia attributable to ex vivo expanded,
intravenously-infused MSCs has never been reported in a human
Figure 4. Soft agar colony forming assay to detect malignant trans-
formation. Representative photographs of triplicate agar plates for
each condition are shown. The positive control was a human ES-2
ovarian clear cell carcinoma cell line. The negative control was
saline. Original magnification was 346. Abbreviations: IFNg, inter-
feron g; MSCs, mesenchymal stem/stromal cells.
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Figure 5. Analysis of hematopoietic engraftment after cotransplantation of hematopoietic cells and MSCs or gMSCs. C57BL/6 mice were
lethally irradiated and then transplanted with 2 3 106 unfractionated GFP-expressing C57BL/6 marrow cells and 250,000 GMP-manufactured
human MSCs or gMSCs (both clinical products) or 250,000 murine MSCs or gMSCs. (A): Kinetics of leukocyte recovery after transplantation
for each cohort of mice. The control mice underwent hematopoietic cell transplantation, but did not receive MSC/gMSC cotransplantation.
n.s., not significant. (B): The absolute lymphocyte count of each cohort assessed 21 days after transplantation. The values represent the
mean6 standard deviation for each cohort, n5 5, *, p< .05 versus each cohort, one-way ANOVA with Tukey’s post hoc test. (C, top) Repre-
sentative dot plot of flow cytometric analysis of unfractionated marrow harvested 21 days after transplantation revealing the percentage of
donor (GFP-expressing) marrow cells. (bottom) Similar analysis of the lin-sca-11c-kit1 (LSK) cells which demarcate the primitive stem/pro-
genitors cells from marrow. Abbreviations: GFP, green fluorescent protein; FSC, forward scatter; LSK, lin-sca-11c-kit1; mMSCs, murine
mesehcymal stromal cells; hMSCs human mesenchymal stromal cells; g-hMSCs, interferon gamma primed human mesenchymal stromal
cells.
Figure 6. Post-mortem examination. Ten weeks after NSG mice were infused with mesenchymal stem/stromal cells (MSCs)/gMSCs, animals
were sacrificed and underwent complete post-mortem examination. (A): Representative photomicrograph of a histologic section of lung tis-
sue taken at 340 original magnification. This section was taken from a mouse which received gMSCs. (B): Photomicrograph of a histologic
section of spleen showing the osseous metaplasia (white arrows) taken at 3100 original magnification. This section was taken from one of
the two MSC-infused mice where this finding was observed.
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subject. Hence, we regard this observation as an incidental finding
in mice and do not attribute it to the MSCs.
Finally focusing on hematopoietic cell transplantation, our
data suggest that infusing MSCs or gMSCs proximate to hemato-
poietic stem cells did not impair hematopoietic reconstitution,
consistent with MSC clinical data. In an effort to thoroughly assess
the impact of our clinical cell product (human) cells in a murine
transplant model, we assessed both the clinical and similarly pre-
pared murine MSCs/gMSCs. Interestingly, a significantly greater
lymphocyte count was observed in all cell infused mice compared
to controls at 21 days after transplantation. The observation was
most likely due to peripheral expansion of transplanted lympho-
cytes as donor stem cell-derived, newly differentiated lympho-
cytes would not be expected to be circulating at the early time
point. Moreover, the higher cell count must be due to an INFg-
independent activity as both MSC- and gMSC-infused mice had
similarly elevated lymphocytes. Despite the intriguing preclinical
murine observation, the clinical significance, if any, remains to be
determined.
CONCLUSION
Our study has demonstrated a GMP-manufacturing process to
prepare MSCs or gMSCs that can be reliably available at a time
designated in advance while avoiding the potential pitfall of using
cryopreserved, freshly thawed cells. Moreover, for gMSCs, there
seems to be negligible residual INFg after the cell washes obviat-
ing concerns regarding cytokine-related toxicity. While we suggest
our preclinical data is compelling, the definitive proof of safety will
require Phase I clinical trials for specific disease indications.
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